Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of PTK787/ZK222584 [vatalanib] in multiple myeloma

Trial Profile

Phase II study of PTK787/ZK222584 [vatalanib] in multiple myeloma

Phase of Trial: Phase II

Latest Information Update: 20 Dec 2007

At a glance

  • Drugs Vatalanib (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 20 Dec 2007 Status changed from in progress to completed.
    • 19 Dec 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top